HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthZacks Investment Research • 11/05/26
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag EstimatesZacks Investment Research • 11/04/26
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class ProfileGlobeNewsWire • 11/04/26
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/28/26
Harmony Biosciences Grapples With A Leadership Transition That Spooked InvestorsInvestors Business Daily • 10/28/26
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire • 10/20/26
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?Zacks Investment Research • 10/16/26
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious HitInvestors Business Daily • 10/12/26
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy DaysGlobeNewsWire • 10/01/26
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?Zacks Investment Research • 09/03/26
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy CongressGlobeNewsWire • 09/03/26
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare ConferenceGlobeNewsWire • 08/27/26
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy PipelineMarketBeat • 08/14/26
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already ReratedSeeking Alpha • 08/05/26